

NCCN RECOMMENDS HEREDITARY CANCER TESTING FOR PATIENTS WITH PROSTATE CANCER THAT MEET ANY OF THE FOLLOWING^{1,2}:

- Metastatic Prostate Cancer (this includes distant metastasis and regional bed or nodes)
- High/Very High Risk Prostate Cancer
- Gleason Score 7 AND one of the following:
 - Ashkenazi Jewish Ancestry
 - 1 family member with metastatic prostate cancer
 - 1 family member with ovarian cancer
 - 1 family member with pancreatic cancer
 - 1 family member with breast cancer ≤ 50 years old
 - 2 family members on the same side of the family with breast or prostate cancer at any age

MYRIAD
myRisk[®]
Hereditary Cancer

 **myriad**[®]
WHEN DECISIONS MATTER
UROLOGY

1. NCCN[®] Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast and Ovarian V.3.2019.
2. NCCN[®] Clinical Practice Guidelines in Oncology - Prostate Cancer V.2.2019.

MEDICARE COVERS *BRCA* 1/2 TESTING FOR PATIENTS WITH PROSTATE CANCER THAT MEET ANY OF THE FOLLOWING¹:

- Metastatic Prostate Cancer*
- Gleason Score 7+ AND one of the following:
 - Ashkenazi Jewish Ancestry
 - 1 family member with metastatic prostate cancer
 - 1 family member with ovarian cancer
 - 1 family member with pancreatic cancer
 - 1 family member with breast cancer ≤ 50 years old
 - 2 family members on the same side of the family with breast or prostate cancer (Gleason 7+ or metastatic) at any age

*Metastatic prostate cancer is biopsy proven and/or with radiographic evidence and includes distant metastasis and regional bed or nodes. It is not biochemical recurrence.²

1. CMS.gov: <https://www.cms.gov/medicare-coverage-database/details/lcddetails.aspx?LCDId=36163&ver=16&Cntrctr=All&UpdatePeriod=818&bc=AQAAEAAAAAAAA&5.2019>
2. NCCN® Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast and Ovarian V.3.2019.